Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Authors
Yue Liu
Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Yue Liu , Kefeng Ding , Qian Xiao , Jinjie He , Hanguang Hu , Jinlin Du , Yuping Zhu , Jiaqi Chen , Zhuo Liu , Jianping Wang , Lifeng Sun , Dong Xu , Jun Li , Xiujun Liao , Jianwei Wang , Yibo Cai , Cheng Cai , Zhekang Jin , Ying Yuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04080843
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 131)
DOI
10.1200/JCO.2024.42.3_suppl.131
Abstract #
131
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Ke-Feng Ding
Poster
2021 Gastrointestinal Cancers Symposium
Anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: A single-arm, phase II study (ALTER-C-002 trial).
First Author: Ke-Feng Ding
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).
First Author: Jing Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz